Asset Details
Do you wish to reserve the book?
Angiotensin in ECMO patients with refractory shock
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Angiotensin in ECMO patients with refractory shock
Do you wish to request the book?
Angiotensin in ECMO patients with refractory shock
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Angiotensin in ECMO patients with refractory shock
2018
Overview
Changes in receptor signaling, excessive production of nitric oxide, and absolute or relative deficiencies of vasoactive hormones, including cortisol, vasopressin, and angiotensin II, play a role. Interest was re-ignited following the Angiotensin II for the Treatment of Vasodilatory Shock (ATHOS-3) study, a randomized controlled trial in patients with refractory shock which confirmed that Ang II was effective at maintaining mean arterial pressure and reducing norepinephrine requirements without an increase in side effects [1]. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
